IRAK1 and type 2 diabetes mellitus: The T2DM miR-216a-3p inhibitor and T2DM oe-IFN-α2 groups exhibited a decrease in IL-1β, IL-6, and TNF-α levels, reduced expression of TLR2, TLR4, and MyD88 mRNA and protein, as well as decreased p-IRAK1 and p-IRF3 protein levels compared to the T2DM group.